188 related articles for article (PubMed ID: 19795913)
1. Immunoinformatics and modeling perspective of T cell epitope-based cancer immunotherapy: a holistic picture.
Mishra S; Sinha S
J Biomol Struct Dyn; 2009 Dec; 27(3):293-306. PubMed ID: 19795913
[TBL] [Abstract][Full Text] [Related]
2. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge.
Iurescia S; Fioretti D; Fazio VM; Rinaldi M
Biotechnol Adv; 2012; 30(1):372-83. PubMed ID: 21745560
[TBL] [Abstract][Full Text] [Related]
3. Immunoinformatics, molecular modeling, and cancer vaccines.
Mishra S; Sinha S
Methods Mol Biol; 2014; 1184():513-21. PubMed ID: 25048143
[TBL] [Abstract][Full Text] [Related]
4. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
5. Prediction and molecular modeling of T-cell epitopes derived from placental alkaline phosphatase for use in cancer immunotherapy.
Mishra S; Sinha S
J Biomol Struct Dyn; 2006 Oct; 24(2):109-21. PubMed ID: 16928134
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
7. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
[TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines: preclinical studies and novel strategies.
Palena C; Abrams SI; Schlom J; Hodge JW
Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
[TBL] [Abstract][Full Text] [Related]
10. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
11. Wildtype p53-specific antibody and T-cell responses in cancer patients.
Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
[TBL] [Abstract][Full Text] [Related]
12. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides as cancer vaccines.
Sundaram R; Dakappagari NK; Kaumaya PT
Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
[TBL] [Abstract][Full Text] [Related]
15. Mimotope vaccines for cancer immunotherapy.
Sharav T; Wiesmüller KH; Walden P
Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
[TBL] [Abstract][Full Text] [Related]
16. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
18. Computational study on the origin of the cancer immunotherapeutic potential of B and T cell epitope peptides.
Li H; Schaduangrat N; Simeon S; Nantasenamat C
Mol Biosyst; 2017 Oct; 13(11):2310-2322. PubMed ID: 28880325
[TBL] [Abstract][Full Text] [Related]
19. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
